Cite
Walter EB, Talaat KR, Sabharwal C, et al. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. N Engl J Med. 2021;doi: 10.1056/NEJMoa2116298.
Walter, E. B., Talaat, K. R., Sabharwal, C., Gurtman, A., Lockhart, S., Paulsen, G. C., Barnett, E. D., Muñoz, F. M., Maldonado, Y., Pahud, B. A., Domachowske, J. B., Simões, E. A. F., Sarwar, U. N., Kitchin, N., Cunliffe, L., Rojo, P., Kuchar, E., Rämet, M., Munjal, I., Perez, J. L., Frenck, R. W., Lagkadinou, E., Swanson, K. A., Ma, H., Xu, X., Koury, K., Mather, S., Belanger, T. J., Cooper, D., Türeci, �. �., Dormitzer, P. R., Şahin, U., Jansen, K. U., Gruber, W. C. (2021). Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. The New England journal of medicine, . https://doi.org/10.1056/NEJMoa2116298
Walter, Emmanuel B, et al. "Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age." The New England journal of medicine vol. (2021). doi: https://doi.org/10.1056/NEJMoa2116298
Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC, Barnett ED, Muñoz FM, Maldonado Y, Pahud BA, Domachowske JB, Simões EAF, Sarwar UN, Kitchin N, Cunliffe L, Rojo P, Kuchar E, Rämet M, Munjal I, Perez JL, Frenck RW, Lagkadinou E, Swanson KA, Ma H, Xu X, Koury K, Mather S, Belanger TJ, Cooper D, Türeci Ö, Dormitzer PR, Şahin U, Jansen KU, Gruber WC. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. N Engl J Med. 2021 Nov 09; doi: 10.1056/NEJMoa2116298. Epub 2021 Nov 09. PMID: 34752019; PMCID: PMC8609605.
Copy
Download .nbib